Anxiolytic-Like Effects of Antisauvagine-30 in Mice Are Not Mediated by CRF2 Receptors

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Zorrilla, Eric P ^a,c   Roberts, Amanda J ^a   Rivier, Jean E ^b   Koob, George F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISAUVAGINE 30; ASTRESSIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CYCLIC AMP; DYNORPHIN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; FREEZING; GENOTYPE; MALE; MAZE TEST; MENTAL STRESS; MOUSE; NONHUMAN; PREPULSE INHIBITION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DRUG EVALUATION, PRECLINICAL; FREEZING REACTION, CATALEPTIC; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 84883190997     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063942     Document Type: Article

References (67)

1. Fekete EM, Zorrilla EP, (2007) Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 28: 1-27.
2. Zorrilla EP, Koob GF, (2010) Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 15: 371-383.
3. Ruhmann A, Bonk I, Lin CR, Rosenfeld MG, Spiess J, (1998) Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci U S A 95: 15264-15269.
4. Rivier J, Gulyas J, Kirby D, Low W, Perrin MH, et al. (2002) Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem 45: 4737-4747.
5. Higelin J, Py-Lang G, Paternoster C, Ellis GJ, Patel A, et al. (2001) 125I-Antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors. Neuropharmacology 40: 114-122.
6. Brauns O, Brauns S, Zimmermann B, Jahn O, Spiess J, (2002) Differential responsiveness of CRF receptor subtypes to N-terminal truncation of peptidic ligands. Peptides 23: 881-888.
7. Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, et al. (2004) Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists. Biochemistry 43: 3996-4011.
8. Hoare SR, Sullivan SK, Fan J, Khongsaly K, Grigoriadis DE, (2005) Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity. Peptides 26: 457-470.
9. Brauns O, Liepold T, Radulovic J, Spiess J, (2001) Pharmacological and chemical properties of astressin, antisauvagine-30 and alpha-helCRF: significance for behavioral experiments. Neuropharmacology 41: 507-516.
10. Gutknecht E, Hauger RL, Van der Linden I, Vauquelin G, Dautzenberg FM, (2008) Expression, binding, and signaling properties of CRF2(a) receptors endogenously expressed in human retinoblastoma Y79 cells: passage-dependent regulation of functional receptors. J Neurochem 104: 926-936.
11. Refojo D, Schweizer M, Kuehne C, Ehrenberg S, Thoeringer C, et al. (2011) Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 333: 1903-1907.
12. Della-Zuana O, Revereault L, Beck-Sickinger A, Monge A, Caignard DH, et al. (2004) A potent and selective NPY Y5 antagonist reduces food intake but not through blockade of the NPY Y5 receptor. Int J Obes Relat Metab Disord 28: 628-639.
13. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, et al. (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 24: 410-414.
14. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, et al. (2000) Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24: 415-419.
15. Gerlai R, (1996) Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci 19: 177-181.
16. Contet C, Rawlins JN, Deacon RM, (2001) A comparison of 129S2/SvHsd and C57BL/6JOlaHsd mice on a test battery assessing sensorimotor, affective and cognitive behaviours: implications for the study of genetically modified mice. Behav Brain Res 124: 33-46.
17. Voikar V, Koks S, Vasar E, Rauvala H, (2001) Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies. Physiol Behav 72: 271-281.
18. Dockstader CL, van der Kooy D, (2001) Mouse strain differences in opiate reward learning are explained by differences in anxiety, not reward or learning. J Neurosci 21: 9077-9081.
19. Rodgers RJ, Boullier E, Chatzimichalaki P, Cooper GD, Shorten A, (2002) Contrasting phenotypes of C57BL/6JOlaHsd, 129S2/SvHsd and 129/SvEv mice in two exploration-based tests of anxiety-related behaviour. Physiol Behav 77: 301-310.
20. Franklin K, Paxinos G (2007) The Mouse Brain in Stereotaxic Coordinates, 3rd Edition San Diego: Academic Press.
21. Njung'e K, Handley SL, (1991) Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 38: 63-67.
22. File SE, (2001) Factors controlling measures of anxiety and responses to novelty in the mouse. Behav Brain Res 125: 151-157.
23. Kalin NH, Sherman JE, Takahashi LK, (1988) Antagonism of endogenous CRH systems attenuates stress-induced freezing behavior in rats. Brain Res 457: 130-135.
24. Fekete EM, Inoue K, Zhao Y, Rivier JE, Vale WW, et al. (2007) Delayed satiety-like actions and altered feeding microstructure by a selective type 2 corticotropin-releasing factor agonist in rats: intra-hypothalamic urocortin 3 administration reduces food intake by prolonging the post-meal interval. Neuropsychopharmacology 32: 1052-1068.
25. Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, et al. (2000) Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24: 403-409.
26. Valdez GR, Inoue K, Koob GF, Rivier J, Vale W, et al. (2002) Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res 943: 142-150.
27. Valdez GR, Zorrilla EP, Rivier J, Vale WW, Koob GF, (2003) Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res 980: 206-212.
28. Zorrilla EP, Reinhardt LE, Valdez GR, Inoue K, Rivier JE, et al. (2004) Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity. J Pharmacol Exp Ther 310: 1027-1034.
29. Zhao Y, Valdez GR, Fekete EM, Rivier JE, Vale WW, et al. (2007) Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats. J Pharmacol Exp Ther 323: 846-854.
30. Ohata H, Shibasaki T, (2004) Effects of urocortin 2 and 3 on motor activity and food intake in rats. Peptides 25: 1703-1709.
31. Venihaki M, Sakihara S, Subramanian S, Dikkes P, Weninger SC, et al. (2004) Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours. J Neuroendocrinol 16: 411-422.
32. Telegdy G, Kadar K, Toth G, (2011) Anxiolytic action of urocortin 3 fragments in mice. Behav Brain Res 222: 295-298.
33. Tanaka M, Kadar K, Toth G, Telegdy G, (2011) Antidepressant-like effects of urocortin 3 fragments. Brain Res Bull 84: 414-418.
34. Tanaka M, Telegdy G, (2008) Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modified forced swimming test in mice. Brain Res Bull 75: 509-512.
35. Henry B, Vale W, Markou A, (2006) The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci 26: 9142-9152.
36. Takahashi LK, Ho SP, Livanov V, Graciani N, Arneric SP, (2001) Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res 902: 135-142.
37. Pelleymounter MA, Joppa M, Carmouche M, Cullen MJ, Brown B, et al. (2000) Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. J Pharmacol Exp Ther 293: 799-806.
38. Miragaya JR, Harris RB, (2008) Antagonism of corticotrophin-releasing factor receptors in the fourth ventricle modifies responses to mild but not restraint stress. Am J Physiol Regul Integr Comp Physiol 295: R404-416.
39. Sutherland JE, Conti LH, (2011) Restraint stress-induced reduction in prepulse inhibition in Brown Norway rats: role of the CRF2 receptor. Neuropharmacology 60: 561-571.
40. Chance WT, Dayal R, Friend LA, Thomas I, Sheriff S, (2007) Mediation of burn-induced hypermetabolism by CRF receptor-2 activity. Life Sci 80: 1064-1072.
41. Staub DR, Evans AK, Lowry CA, (2006) Evidence supporting a role for corticotropin-releasing factor type 2 (CRF2) receptors in the regulation of subpopulations of serotonergic neurons. Brain Res 1070: 77-89.
42. Risbrough VB, Hauger RL, Roberts AL, Vale WW, Geyer MA, (2004) Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci 24: 6545-6552.
43. Risbrough VB, Hauger RL, Pelleymounter MA, Geyer MA, (2003) Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) 170: 178-187.
44. Pelleymounter MA, Joppa M, Ling N, Foster AC, (2002) Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. J Pharmacol Exp Ther 302: 145-152.
45. Takahashi C, Ohata H, Shibasaki T, (2011) Corticotropin-releasing factor (CRF) receptor subtypes in mediating neuronal activation of brain areas involved in responses to intracerebroventricular CRF and stress in rats. Peptides 32: 2384-2393.
46. Sekino A, Ohata H, Mano-Otagiri A, Arai K, Shibasaki T, (2004) Both corticotropin-releasing factor receptor type 1 and type 2 are involved in stress-induced inhibition of food intake in rats. Psychopharmacology (Berl) 176: 30-38.
47. Maruyama H, Makino S, Noguchi T, Nishioka T, Hashimoto K, (2007) Central type 2 corticotropin-releasing hormone receptor mediates hypothalamic-pituitary-adrenocortical axis activation in the rat. Neuroendocrinology 86: 1-16.
48. Navarro-Zaragoza J, Nunez C, Ruiz-Medina J, Laorden ML, Valverde O, et al. (2011) CRF(2) mediates the increased noradrenergic activity in the hypothalamic paraventricular nucleus and the negative state of morphine withdrawal in rats. Br J Pharmacol 162: 851-862.
49. Cooper MA, Huhman KL, (2010) Blocking corticotropin-releasing factor-2 receptors, but not corticotropin-releasing factor-1 receptors or glucocorticoid feedback, disrupts the development of conditioned defeat. Physiol Behav 101: 527-532.
50. Chen CY, Inui A, Asakawa A, Fujino K, Kato I, et al. (2005) Des-acyl ghrelin acts by CRF type 2 receptors to disrupt fasted stomach motility in conscious rats. Gastroenterology 129: 8-25.
51. Cullen MJ, Ling N, Foster AC, Pelleymounter MA, (2001) Urocortin, corticotropin releasing factor-2 receptors and energy balance. Endocrinology 142: 992-999.
52. Lam MP, Gianoulakis C, (2011) Effects of corticotropin-releasing hormone receptor antagonists on the ethanol-induced increase of dynorphin A1-8 release in the rat central amygdala. Alcohol 45: 621-630.
53. Lam MP, Gianoulakis C, (2011) Effects of acute ethanol on corticotropin-releasing hormone and beta-endorphin systems at the level of the rat central amygdala. Psychopharmacology (Berl) 218: 229-239.
54. Sananbenesi F, Fischer A, Schrick C, Spiess J, Radulovic J, (2003) Mitogen-activated protein kinase signaling in the hippocampus and its modulation by corticotropin-releasing factor receptor 2: a possible link between stress and fear memory. J Neurosci 23: 11436-11443.
55. Radulovic J, Ruhmann A, Liepold T, Spiess J, (1999) Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci 19: 5016-5025.
56. Todorovic C, Radulovic J, Jahn O, Radulovic M, Sherrin T, et al. (2007) Differential activation of CRF receptor subtypes removes stress-induced memory deficit and anxiety. Eur J Neurosci 25: 3385-3397.
57. Sahuque LL, Kullberg EF, McGeehan AJ, Kinder JR, Hicks MP, et al. (2006) Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes. Psychopharmacology (Berl) 186: 122-132.
58. Cooper MA, Huhman KL, (2007) Corticotropin-releasing factor receptors in the dorsal raphe nucleus modulate social behavior in Syrian hamsters. Psychopharmacology (Berl) 194: 297-307.
59. Hammack SE, Schmid MJ, LoPresti ML, Der-Avakian A, Pellymounter MA, et al. (2003) Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress. J Neurosci 23: 1019-1025.
60. Turek VF, Ryabinin AE, (2005) Ethanol versus lipopolysaccharide-induced hypothermia: involvement of urocortin. Neuroscience 133: 1021-1028.
61. Bledsoe AC, Oliver KM, Scholl JL, Forster GL, (2011) Anxiety states induced by post-weaning social isolation are mediated by CRF receptors in the dorsal raphe nucleus. Brain Res Bull 85: 117-122.
62. Scholl JL, Vuong SM, Forster GL, (2010) Chronic amphetamine treatment enhances corticotropin-releasing factor-induced serotonin release in the amygdala. Eur J Pharmacol 644: 80-87.
63. Vuong SM, Oliver HA, Scholl JL, Oliver KM, Forster GL, (2010) Increased anxiety-like behavior of rats during amphetamine withdrawal is reversed by CRF2 receptor antagonism. Behav Brain Res 208: 278-281.
64. Forster GL, Pringle RB, Mouw NJ, Vuong SM, Watt MJ, et al. (2008) Corticotropin-releasing factor in the dorsal raphe nucleus increases medial prefrontal cortical serotonin via type 2 receptors and median raphe nucleus activity. Eur J Neurosci 28: 299-310.
65. Lukkes JL, Forster GL, Renner KJ, Summers CH, (2008) Corticotropin-releasing factor 1 and 2 receptors in the dorsal raphe differentially affect serotonin release in the nucleus accumbens. Eur J Pharmacol 578: 185-193.
66. Ohata H, Shibasaki T, (2011) Involvement of CRF2 receptor in the brain regions in restraint-induced anorexia. Neuroreport 22: 494-498.
67. Amat J, Tamblyn JP, Paul ED, Bland ST, Amat P, et al. (2004) Microinjection of urocortin 2 into the dorsal raphe nucleus activates serotonergic neurons and increases extracellular serotonin in the basolateral amygdala. Neuroscience 129: 509-519.